William Blair Initiates Coverage On NewAmsterdam Pharma with Outperform Rating

William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.

William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.

Total
0
Shares
Related Posts